Pro-inflammatory mediators and enzymes

Pro-inflammatory mediators and enzymes encompass a broad spectrum of biological molecules that drive the inflammatory response, including cytokines, chemokines, and lipid-derived signaling molecules [StatPearls, 2023]. Key enzymes in this category, such as cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS), catalyze the production of potent inflammatory agents like prostaglandins and nitric oxide [NCBI, 2022]. Cytokines such as Tumor Necrosis Factor-alpha (TNF-α), Interleukin-1 (IL-1), and Interleukin-6 (IL-6) act as primary signaling proteins that coordinate the recruitment and activation of immune cells [Nature Reviews Drug Discovery, 2017]. While these mediators are essential for host defense and wound healing, their chronic or excessive production is a primary driver of tissue damage in autoimmune and autoinflammatory diseases [PubMed, 2021]. Therapeutic intervention typically involves the use of small molecules to inhibit enzymatic activity or monoclonal antibodies to neutralize specific cytokines or their receptors [Frontiers in Pharmacology, 2020]. By targeting these mediators, clinicians can reduce systemic inflammation and mitigate the progression of chronic conditions such as rheumatoid arthritis and inflammatory bowel disease [StatPearls, 2023]. However, because these molecules also play roles in normal immune surveillance, their inhibition can lead to side effects such as increased susceptibility to infection [Nature Reviews Rheumatology, 2018].

Other names

Inflammatory mediatorsPro-inflammatory factorsInflammatory enzymesPro-inflammatory cytokines and enzymes

Drugs targeting this group act through several distinct mechanisms: small molecule inhibition of enzymatic activity (e.g., NSAIDs inhibiting COX-2), monoclonal antibody-mediated neutralization of circulating cytokines (e.g., anti-TNF or anti-IL-6 biologics), or competitive antagonism of cytokine receptors (e.g., IL-1 receptor antagonists) [StatPearls, 2023; Frontiers in Pharmacology, 2020].